Contact: +91-9711224068
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Pharmacology and Pharmaceutical Sciences

Vol. 6, Issue 1, Part A (2024)

Development of erythromycin stearate invasomes for dermal infection

Author(s):

B Kamaleshwari, M Ashok Kumar, S Boopathi, P Eswaran, T Kabilan, S Sivasankaravadivelan and G Kaviya

Abstract:

Erythromycin stearate, a macrolide antibiotic, exerts its effect by inhibiting bacterial protein synthesis. Topically Erythromycin stearate is used to treat bacterial skin infections. Erythromycin stearate is a BCS class III Drug (High solubility and low permeability). Hence Invasomes are suitable to increase the penetration of Erythromycin stearate to treat deep skin infections. Invasomes are novel vesicular systems that exhibit improved transdermal penetration compared to conventional liposomes. Invasomes contain phospholipids, ethanol and terpenes. Erythromycin stearate Invasomes are prepared with soy lecithin and various concentrations of terpenes, citral and eugenol. The Fourier-transform infrared spectroscopy study was carried out to determine the compatibility of Erythromycin stearate with the excipients. Zone of inhibition is carried out for Erythromycin stearate against Staphylococcus aureus. The Erythromycin stearate Invasomes are prepared by mechanical dispersion method. Formulated Invasomes are evaluated for particle size, zeta potential, entrapment efficiency, drug content, In vitro drug release and anti-microbial activity.

Pages: 13-20  |  38 Views  15 Downloads


International Journal of Pharmacology and Pharmaceutical Sciences
How to cite this article:
B Kamaleshwari, M Ashok Kumar, S Boopathi, P Eswaran, T Kabilan, S Sivasankaravadivelan and G Kaviya. Development of erythromycin stearate invasomes for dermal infection. Int. J. Pharmacol. Pharm. Sci. 2024;6(1):13-20. DOI: 10.33545/26647206.2024.v6.i1a.16
Call for book chapter